Drug Type Small molecule drug |
Synonyms CT-707, SY-707 |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), FAK1 inhibitors(Focal adhesion kinase 1 inhibitors), IGF-1R antagonists(Insulin-like growth factor I receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H45N9O3S |
InChIKeyNPJCURIANJMFEO-UHFFFAOYSA-N |
CAS Registry1384860-29-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ALK positive Non-Small Cell Lung Cancer | Phase 3 | CN | 24 Jun 2020 | |
Pancreatic Cancer | Phase 2 | CN | 19 Oct 2022 |
NCT02695550 (Pubmed) Manual | Phase 1 | 60 | (ALK TKI-naïve) | yboqkoggam(jcvblhxtzq) = MTD was not reached fcjvnktoib (lazkeofxck ) View more | Positive | 23 Nov 2022 | |
(received crizotinib previously) | |||||||
Phase 1 | 13 | nzgdixecjr(lvwydkufey) = diarrhea 92%, elevated aspartate aminotransferase 61%, elevated alanine aminotransferase 54%, hair loss 38%, vomiting 31% qvnlqhczzr (tzafnsjdie ) View more | Positive | 23 Nov 2019 | |||
Phase 1 | ALK positive Non-Small Cell Lung Cancer ALK Positive | 23 | ixtvbzvjis(hzsizpbgqt) = none jimvyseuto (wpuovxzddz ) View more | Positive | 18 Nov 2017 |